Maybe I can elaborate just a little bit more.
To deal with just two specific increases, the increase is mainly due to a transfer from Health Canada to provide for analysis of price utilization and cost trends under the national prescription drug utilization information system. That's $1.35 million. There was another transfer from Health Canada to monitor and report on the prices of non-patented prescription drugs in Canada, for $0.6 million.
On the latter item, you will know that the national pharmaceuticals strategy, with the concern about the cost of pharmaceuticals, has started to focus in on the cost of generic pharmaceuticals, where we seem to have comparatively higher generic pricing than some other countries. The idea was to have the board do some initial monitoring in advance of looking at policy options on how best to deal with that issue.